MONT-R 随机试验:高危局部晚期直肠癌新辅助放化疗中 CapeOX 与卡培他滨的长期结果
多中心开放标签随机对照试验纳入 505 例高危局部晚期直肠癌患者,随机接受长程放疗联合 3 周期 CapeOX 或单药卡培他滨新辅助治疗。CapeOX 组显著提高 CAP 0-1 肿瘤消退比例,但两组病理完全缓解率、3 年无病生存和总生存均无显著差异,且未显著增加严重不良事件。
要点
- 两组病理完全缓解率、3 年无病生存和总生存均无显著差异。
核心结论
- 在高危局部晚期直肠癌新辅助放化疗中加入奥沙利铂可增强病理肿瘤消退,但未转化为长期生存获益。
研究设计与样本
- 多中心、开放标签、随机对照试验,纳入 505 例高危局部晚期直肠癌患者,随机分为 CapeOX 组(n=248)和卡培他滨组(n=257)。
关键数值与推荐
- 高危局部晚期直肠癌定义为至少具备以下一项不良特征:临床 T4 期、临床 N2 期、高肿瘤分级、肠壁外血管侵犯、直肠系膜筋膜受累或肛周肌肉受累。
临床怎么用
- 对于高危局部晚期直肠癌,CapeOX 新辅助放化疗可提高病理肿瘤消退,但未显著改善长期生存,需权衡毒性后个体化选择。
- 治疗后病理肿瘤消退程度(CAP 分级)与 3 年无病生存相关,可用于预后评估。
局限性
- 中位随访 37 个月,长期生存数据尚不成熟;开放标签设计可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The clinical benefit of incorporating oxaliplatin into conventional neoadjuvant chemoradiotherapy (nCRT) for patients with high-risk locally advanced rectal cancer (LARC) remains controversial. METHODS AND MATERIALS: This multicenter, open-label, randomized controlled trial enrolled 505 patients with high-risk LARC, defined by the presence of at least 1 of the following adverse features: clinical T4 stage, clinical N2 stage, high tumor grade, extramural vascular invasion, involvement of the mesorectal fascia, or perianal musculature involvement. Enrollment took place between August 2017 and April 2022. Patients were randomly assigned to receive long-course radiation therapy combined with a 3-cycle chemotherapy regimen of capecitabine and oxaliplatin (CapeOX group; n = 248) or capecitabine alone (Cape group; n = 257). The primary endpoint was 3-year disease-free survival (3y-DFS). RESULTS: Following nCRT, radical surgery was performed in 91.5% of the CapeOX group and 92.2% in the Cape group (P = .778). Pathologic complete response rates were comparable between the CapeOX and Cape groups (25.5% vs 25.3%; P = .954). A significantly greater proportion of patients in the CapeOX group achieved marked tumor regression (College of American Pathologists (CAP 0-1)) compared with the Cape group (58.6% vs 46.8%; P = .011). The incidence of grade 3 to 4 treatment-related toxicities was similar between the groups (CapeOX: 14.1% vs Cape: 9.3%; P = .095). After a median follow-up of 37 months, 3y-DFS and 3-year overall survival rates were comparable between the groups (both P > .050). Overall, patients who achieved CAP 0 to 1 had significantly better 3y-DFS than those with CAP 2 to 3 (89.0% vs 80.9%; P = .018). CONCLUSIONS: The addition of oxaliplatin to conventional nCRT may enhance pathologic tumor regression in patients with high-risk LARC without a significant increase in severe adverse events. However, this intensified 3-cycle chemotherapy regimen did not translate into a long-term survival benefit.
引用
- Zhou J, Li G, Jia W, et al. CapeOX Versus Capecitabine in Neoadjuvant Chemoradiation for High-Risk Locally Advanced Rectal Cancer: Long-Term Results From the MONT-R Randomized Controlled Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 41352689. doi:10.1016/j.ijrobp.2025.11.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。